Wang C.,Hebei University of Technology |
Liu Y.,Hebei University of Technology |
Niu X.,Hebei University of Technology |
Tian J.,Zhongqi Pharmaceutical Technology Shijiazhuang Co. |
And 2 more authors.
Journal of Semiconductors | Year: 2012
We have developed an alkaline barrier slurry (named FA/O slurry) for barrier removal and evaluated its chemical mechanical planarization (CMP) performance through comparison with a commercially developed barrier slurry. The FA/O slurry consists of colloidal silica, which is a complexing and an oxidizing agent, and does not have any inhibitors. It was found that the surface roughness of copper blanket wafers polished by the FA/O slurry was lower than the commercial barrier slurry, demonstrating that it leads to a better surface quality. In addition, the dishing and electrical tests also showed that the patterned wafers have a lower dishing value and sheet resistance as compared to the commercial barrier slurry. By comparison, the FA/O slurry demonstrates good planarization performance and can be used for barrier CMP. © 2012 Chinese Institute of Electronics. Source
Guo P.,Hebei Medical University |
Dong L.,Hebei Medical University |
Yan W.,Hebei Medical University |
Wei J.,Zhongqi Pharmaceutical Technology Shijiazhuang Co. |
And 2 more authors.
Biomedical Chromatography | Year: 2015
A sensitive and reproducible liquid chromatography tandem mass spectrometry (LC-MS/MS) method was developed and validated for the simultaneous determination of linarin, naringenin and formononetin in rat plasma after addition of sulfamethoxazole as the internal standard (IS). Separation was carried out on a Diamonsil C18 column (150×4.6 mm, 5 μm) with liner gradient elution using methanol (A) and 0.5‰ formic acid aqueous solution (B). Detection was performed on a triple-quadrupole linear ion trap mass spectrometer with the negative ion electrospray ionization in multiple-reaction monitoring (MRM) mode. The MRM transitions were m/z 591.2→283.2, 271.0→150.9, 266.9→252.0 and 252.0→155.9 for linarin, naringenin, formononetin and IS, respectively. All analytes showed good linearity within the concentration range (r>0.9973). The lower limits of quantitation of linarin, naringenin and formononetin were 0.64, 1.07 and 1.04 ng/mL, respectively. Intra-day and inter-day precisions of the investigated components exhibited an RSD within 9.96%, and the accuracy (relative error) ranged from -11.25 to 9.38% at all quality control levels. The developed method was successfully applied to a pharmacokinetic study of linarin, naringenin and formononetin in rats after oral administration of Bushen Guchi Pill. © 2014 John Wiley & Sons, Ltd. Source
Cao G.,Beijing Hospital |
Ying P.,Zhongqi Pharmaceutical Technology Shijiazhuang Co. |
Yan B.,Beijing Hospital |
Xue W.,Beijing Hospital |
And 5 more authors.
Journal of Ethnopharmacology | Year: 2015
Ethnopharmacological relevance Pinocembrin is the most abundant flavonoid in propolis. Preclinical studies have suggested that pinocembrin protects rat brain against oxidation and apoptosis induced by ischemia-reperfusion both in vivo and in vitro. To investigate the safety, tolerability and pharmacokinetics of a new neuroprotective agent, pinocembrin. Materials and method A double-blind, placebo-controlled, randomized study was carried out in 58 healthy subjects. Single ascending doses of pinocembrin (20-150 mg) were evaluated in 5 cohorts. Multi-dose was studied at pinocembrin 60 mg. Results Pinocembrin was well tolerated. No serious adverse events occurred. No subjects were discontinued because of a treatment emergent AE. Treatment related adverse event was acute urticaria. Two subjects in 150 mg cohort developed grade II urticaria during the study. One subject discontinued after 3 days at 60 mg bid because of diarrhea. In the single-dose study, the mean peak plasma pinocembrin concentration was obtained at the end of the 30-min infusion. The Cmax ranged from 0.28 μg mL-1 to 2.46 μg mL-1. AUC (0,∞) ranged from 10.34 μg mL-1 min to 89.34 μg mL-1 min. The T1/2 was similar across 5 dose groups, ranging from 40 to 55 min. Both urinary and feces excretion levels of pinocembrin were extremely low and similar among each dose groups, with mean values ranging from 0.07% to 0.17% and 0.94% to 1.94% of the administered dose, respectively. Linear increases in Cmax and AUC(0,∞) were observed. The pharmacokinetics of pinocembrin in multiple-dose was similar to those observed in the single-dose study, with no evidence of accumulation. Both urinary and feces excretion levels of pinocembrin were extremely low. Conclusions Pinocembrin displayed linear plasma pharmacokinetics over the dose range, 20-150 mg and was well tolerated up to 120 mg day-1 when administered intravenously to healthy adults. No major safety concerns were identified that would preclude further clinical development of pinocembrin injection. © 2015 Elsevier Ireland Ltd. Source